Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: PTH 1-34 Clear all
Completed No phase listed Observational

A Registry for Participants With Chronic Hypoparathyroidism

NCT01922440
View directory record Official record
Conditions
Hypoparathyroidism
Interventions
No intervention
Other
Lead sponsor
Takeda
Industry
Eligibility
Not listed
Enrollment
1,339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
54
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 2, 2026, 10:54 AM EDT
Withdrawn Not applicable Interventional

The Effects of Therapy With Teriparatide on Vascular Compliance and Osteoprotegerin/RANKL

NCT00347737
View directory record Official record
Conditions
Osteoporosis
Interventions
teriparatide
Drug
Lead sponsor
Leland Graves III, MD
Other
Eligibility
40 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Sep 2, 2026, 10:54 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Comparison Study of PTHrP and PTH to Treat Osteoporosis

NCT00853723
View directory record Official record
Conditions
Osteoporosis
Interventions
Parathyroid hormone related protein(1-36), Parathyroid hormone (1-34)
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
45 Years to 75 Years · Female only
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 23, 2016 · Synced Sep 2, 2026, 10:54 AM EDT
Terminated Phase 2 Interventional Results available

A Phase II Study Evaluating SB-751689 in Post-Menopausal Women With Osteoporosis.

NCT00471237
View directory record Official record
Conditions
Osteoporosis
Interventions
Ronacaleret, Teriparatide, Alendronate
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years · Female only
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
9
States / cities
Oakland, California • Palm Desert, California • Walnut Creek, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Sep 2, 2026, 10:54 AM EDT
Terminated Phase 3 Interventional Results available

Effects of PTH Replacement on Bone in Hypoparathyroidism

NCT00395538
View directory record Official record
Conditions
Hypoparathyroidism, DiGeorge Syndrome
Interventions
PTH 1-34
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 2, 2026, 10:54 AM EDT
Completed Phase 2 Interventional

A Safety and Efficacy Study of a Topical Gel for the Treatment of Mild to Moderate Psoriasis

NCT00593177
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
PTH (1-34) Gel / Placebo Gel
Drug
Lead sponsor
Manhattan Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
4
States / cities
San Diego, California • Ormond Beach, Florida • Fridley, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2008 · Synced Sep 2, 2026, 10:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Racial Differences in Phosphorus Metabolism

NCT00856726
View directory record Official record
Conditions
Control
Interventions
1-34 parathyroid infusion
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 10, 2017 · Synced Sep 2, 2026, 10:54 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Hypoparathyroidism With Synthetic Human Parathyroid Hormone 1-34

NCT00001304
View directory record Official record
Conditions
Hypoparathyroidism
Interventions
Synthetic Human Parathyroid Hormone 1-34, Calcitriol & Calcium
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
17 Years to 69 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Sep 2, 2026, 10:54 AM EDT
Completed Phase 3 Interventional Results available

Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption

NCT03710889
View directory record Official record
Conditions
Osteoporosis, Postmenopausal, Osteoporosis, Osteoporosis Vertebral, Osteoporosis Risk, Osteoporosis Fracture, Osteoporosis Localized to Spine, Osteoporosis, Age-Related, Osteoporosis Senile, Osteoporosis of Vertebrae
Interventions
Abaloparatide
Drug
Lead sponsor
Radius Health, Inc.
Industry
Eligibility
50 Years to 85 Years · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Golden, Colorado • Gainesville, Georgia • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Sep 2, 2026, 10:54 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

One Week Comparison Study of PTH and PTHrP Infusions

NCT01333267
View directory record Official record
Conditions
Osteoporosis, Hypercalcemia of Malignancy, Hyperparathyroidism, Bone Diseases, Endocrine
Interventions
Parathyroid Hormone-related Protein (1-36), parathyroid hormone (1-34), PTH (1-34) and PTHrP (1-36)
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
24 Years to 35 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 4, 2014 · Synced Sep 2, 2026, 10:54 AM EDT
Completed Phase 2 Interventional Results available

PTH(1-34) and Pelvic Fracture Healing - a Randomized Controlled Trial

NCT02972424
View directory record Official record
Conditions
Osteoporotic Fractures
Interventions
Teriparatide Prefilled Syringe, Placebo
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
65 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Sep 2, 2026, 10:54 AM EDT
Completed Phase 2 Interventional Results available

Comparing Pump With Subcutaneous Injection Delivery of PTH 1-34 in the Management of Chronic Hypoparathyroidism

NCT00743782
View directory record Official record
Conditions
Hypoparathyroidism, Hypocalcemia, Autoimmune Polyendocrine Syndrome Type 1, Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Interventions
Synthetic Human Parathyroid Hormone 1-34 pump
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
7 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 2, 2026, 10:54 AM EDT
Completed Phase 3 Interventional Results available

A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism

NCT04701203
View directory record Official record
Conditions
Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
Interventions
TransCon PTH, Placebo
Combination Product
Lead sponsor
Ascendis Pharma Bone Diseases A/S
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
9
States / cities
San Francisco, California • Chicago, Illinois • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 2, 2026, 10:54 AM EDT
Active, not recruiting Phase 4 Interventional

Novel Combination Therapy for Osteoporosis in Men

NCT03994172
View directory record Official record
Conditions
Male Osteoporosis
Interventions
Teriparatide or human parathyroid hormone (PTH) 1-34, Cinacalcet, placebo tablet, Calcium citrate tablet, Vitamin D3
Drug · Dietary Supplement
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
60 Years to 85 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Sep 2, 2026, 10:54 AM EDT
Completed Phase 4 Interventional Results available

Use of Forteo (Teriparatide) in Posterolateral Lumbar Spine Fusion

NCT01292252
View directory record Official record
Conditions
Lumbar Spondylosis, Lumbar Spondylolisthesis, Adult Degenerative Lumbar Scoliosis
Interventions
teriparatide, Placebo
Biological
Lead sponsor
Shane Burch
Other
Eligibility
60 Years to 90 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 2, 2021 · Synced Sep 2, 2026, 10:54 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

7 Day Continuous Parathyroid Hormone IV Infusion

NCT00377312
View directory record Official record
Conditions
Osteoporosis, Bone Diseases, Endocrine, Hyperparathyroidism
Interventions
Parathyroid Hormone (1-34)
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
24 Years to 35 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Sep 2, 2026, 10:54 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Forteo for the Treatment of Unexplained Osteoporosis in Premenopausal Women

NCT00697463
View directory record Official record
Conditions
Menopause, Fracture, Osteoporosis
Interventions
Teriparatide (PTH 1-34)
Drug
Lead sponsor
Columbia University
Other
Eligibility
20 Years to 48 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
2
States / cities
Omaha, Nebraska • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Sep 2, 2026, 10:54 AM EDT
Recruiting Phase 3 Interventional

A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism

NCT07081997
View directory record Official record
Conditions
Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
Interventions
Palopegteriparatide Experimental Arm, Palopegteriparatide Control Arm
Combination Product
Lead sponsor
Ascendis Pharma Bone Diseases A/S
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Chicago, Illinois • Minneota, Minnesota • Reno, Nevada + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 2, 2026, 10:54 AM EDT
Completed Phase 2 Interventional

Can Parathyroid Hormone Injections Reverse Glucocorticoid-induced Osteoporosis

NCT00004993
View directory record Official record
Conditions
Osteoporosis
Interventions
Parathyroid hormone (hPTH 1-34)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 1, 2010 · Synced Sep 2, 2026, 10:54 AM EDT
Completed Phase 2 Interventional Results available

A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism

NCT04009291
View directory record Official record
Conditions
Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
Interventions
TransCon PTH, Placebo for TransCon PTH
Combination Product
Lead sponsor
Ascendis Pharma A/S
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
5
States / cities
Chicago, Illinois • Rochester, Minnesota • Great Neck, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 2, 2026, 10:54 AM EDT
Completed Phase 2 Interventional Results available

Parathyroid Hormone (PTH) for Osteoporosis in Postmenopausal Women

NCT00086619
View directory record Official record
Conditions
Postmenopausal Osteoporosis, Osteoporosis
Interventions
synthetic hPTH 1-34
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
46 Years to 85 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 29, 2013 · Synced Sep 2, 2026, 10:54 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Combination Osteogenic Therapy in Established Osteoporosis

NCT00018447
View directory record Official record
Conditions
Osteoporosis, Post-Menopausal
Interventions
PTH 1-34, MFPSR-fluoride
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
60 Years to 80 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2003
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2009 · Synced Sep 2, 2026, 10:54 AM EDT
Completed Phase 4 Interventional Results available

Risedronate and Parathyroid Hormone to Reverse Osteoporosis Caused by Chronic Steroid Use

NCT00221299
View directory record Official record
Conditions
Osteoporosis
Interventions
Risedronate, Parathyroid Hormone
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2015 · Synced Sep 2, 2026, 10:54 AM EDT
Completed Phase 1 Interventional

Impact of Parathyroid Hormone (PTH) on Osseous Cavity

NCT00277706
View directory record Official record
Conditions
Bone Loss, Periodontitis
Interventions
Periodontal surgery, FORTEO, Placebo, Vitamin D and Calcium
Procedure · Drug · Dietary Supplement
Lead sponsor
University of Michigan
Other
Eligibility
30 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 6, 2009 · Synced Sep 2, 2026, 10:54 AM EDT